|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not
intended to be used as a source of information on on healthcare or medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines
or the package leaflet of your medicine. For up-to-date information on other
healthcare topics, please consult the relevant reliable sources or an healthcare
expert, such as a physician etc.
|
BACK TO LIST |
Laboratory Report
|
|
|
|||||||||||||||||||||||||
Hematology
| Test | 31-JUL-2024 | Reference Range | Unit |
|---|---|---|---|
| Leukocytes [#/volume] in Blood by Automated count | 3.5 L | 4.5 - 11.0 | 10*3/uL |
| Erythrocytes [#/volume] in Blood by Automated count | 4.8 | 4.3 - 5.7 | 10*6/uL |
| Hemoglobin [Mass/volume] in Blood | 16.0 | 13.5 - 17.5 | g/dL |
| Hematocrit [Volume Fraction] of Blood by Automated count | 45.9 | 39 - 50 | % |
| MCV [Entitic mean volume] in Red Blood Cells by Automated count | 91.7 | 80 - 100 | fL |
| MCH [Entitic mass] by Automated count | 31.3 | 27 - 33 | pg |
| MCHC [Entitic Mass/volume] in Red Blood Cells by Automated count | 34.1 | 32 - 36 | g/dL |
| Erythrocyte [DistWidth] in Blood by Automated count | 13.9 | 11.5 - 14.5 | % |
| Platelets [#/volume] in Blood by Automated count | 158.3 | 150 - 450 | 10*3/uL |
Chemistry
| Test | 31-JUL-2024 | Reference Range | Unit |
|---|---|---|---|
| Glucose [Mass/volume] in Serum or Plasma | 98.1 | 70 - 100 | mg/dL |
| Urea nitrogen [Mass/volume] in Serum or Plasma | 18.5 | 7 - 20 | mg/dL |
| Creatinine [Mass/volume] in Serum or Plasma | 2.7 H | 0.6 - 1.3 | mg/dL |
| Calcium [Mass/volume] in Serum or Plasma | 9.0 | 8.6 - 10.3 | mg/dL |
| Sodium [Moles/volume] in Serum or Plasma | 136.8 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Serum or Plasma | 3.8 | 3.5 - 5.1 | mmol/L |
| Chloride [Moles/volume] in Serum or Plasma | 108.6 H | 98 - 107 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Serum or Plasma | 22.5 | 22 - 29 | mmol/L |
| Protein [Mass/volume] in Serum or Plasma | 8.1 | 6.6 - 8.3 | g/dL |
| Albumin [Mass/volume] in Serum or Plasma | 4.5 | 3.5 - 5.5 | g/dL |
| Bilirubin.total [Mass/volume] in Serum or Plasma | 12.7 H | 0.1 - 1.2 | mg/dL |
| Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 61.9 | 30 - 120 | U/L |
| Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 36.3 | 10 - 40 | U/L |
| Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21.1 | 10 - 40 | U/L |
| Magnesium [Mass/volume] in Serum or Plasma | 2.0 | 1.6 - 2.6 | mg/dL |
| Phosphate [Mass/volume] in Serum or Plasma | 2.9 | 2.5 - 4.5 | mg/dL |
| pH of Arterial blood | 7.2 L | 7.35 - 7.45 | [pH] |
| Carbon dioxide [Partial pressure] in Arterial blood | 42.0 | 35 - 45 | mm[Hg] |
| Oxygen [Partial pressure] in Arterial blood | 81.0 | 80 - 100 | mm[Hg] |
| Bicarbonate [Moles/volume] in Arterial blood | 23.6 | 22 - 28 | mmol/L |
| Oxygen saturation in Arterial blood | 97.0 | 95 - 100 | % |
| Cholesterol [Mass/volume] in Serum or Plasma | 160.6 | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 138.6 | 0 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 80.3 | 0 - 100 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52.5 | 40 - 60 | mg/dL |
Coagulation
| Test | 31-JUL-2024 | Reference Range | Unit |
|---|---|---|---|
| Prothrombin time (PT) | 11.2 | 11.0 - 13.5 | s |
| INR in Platelet poor plasma by Coagulation assay | 1.1 | 0.9 - 1.1 | {INR} |
| aPTT in Blood by Coagulation assay | 32.3 H | 24 - 32 | s |
Annotation
| Conclusion and Recommendations based on this report and previous findings known to us |
|---|
| The patient shows leukopenia, markedly elevated creatinine, hyperbilirubinemia, mild hyperchloremia, prolonged aPTT, and metabolic acidosis (low pH, normal pCO₂, low-normal bicarbonate). These findings suggest significant renal dysfunction, possible hepatic dysfunction or cholestasis, and increased bleeding risk. Immediate clinical correlation and further evaluation are recommended. |